Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)
Phase of Trial: Phase IV
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Empagliflozin (Primary) ; Linagliptin (Primary) ; Sulodexide (Primary) ; Telmisartan (Primary)
- Indications Proteinuria
- Focus Therapeutic Use
- Acronyms ROTATE-2
- 05 Oct 2017 Planned End Date changed to 26 Aug 2018.
- 05 Oct 2017 Planned number of patients changed to 52.
- 05 Oct 2017 New trial record